ClinicalTrials.gg
RecruitingNCT06808451Updated Nov 5, 2026

Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture

An interventional study of DNA PCR and Urine Culture in Urinary Tract Infections, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Planned enrollment
101st of 225
136 · median 100
Started
2025
with 13 others
No phase
94 of 275
19 open now
Primary completion
2027-05
later than 24 of 56 live
Registered
243rd of 275
by date

Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 101st largest by planned enrollment of the 225 interventional ones that give a count, is one of 14 that started in 2025, is one of 94 with no phase, reaches primary completion later than 24 of the 56 other live ones, and was the 243rd registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • urine culture
  • DNA PCR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women 18 years and older
  • Presenting to clinic with symptoms of UTI or cystitis
  • Patients with Medicare and Medicaid insurance

Exclusion criteria

Exclusion Criteria:

  • Urinary diversion of any type
  • Chronic indwelling urinary catheter
  • Diagnosed UTI within the previous 21 days
  • Antibiotic therapy within the previous 21 days
  • Use of phenazopyridine within the previous 21 days
  • Commercial insurance
  • Non-English speaking
  • Pregnant patients
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    DNA Polymerase Chain Reaction (PCR)

    Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.

    Device: DNA PCR

  • Active comparator
    Urine Culture

    Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.

    Diagnostic Test: Urine Culture

Interventions

  • DeviceDNA PCR

    Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.

  • Diagnostic testUrine Culture

    Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.

06

What researchers measure

Primary outcomes

  1. Change in symptoms as measured by UTI-SIQ-8 questionnaire

    The UTI-SIQ-8 is an eight item questionnaire that asks about symptom severity and symptom impairment on a likert scale from 0 to 4, 0 being not at all and 4 being very strong/very severe.

    Time frame: Baseline, one day after antibiotic completion

  2. Change in symptoms as measured by the UTI Symptom Assessment questionnaire

    The UTI Symptom Assessment questionnaire is a ten item questionnaire that asks about symptom relief, with lower scores indicating less symptoms.

    Time frame: Baseline, one day after antibiotic completion

Secondary outcomes

  1. Length of time from patient presentation to initiation of treatment as measured by medical record review

    Time frame: Up to 21 days

  2. Number of antibiotic changes as measured by medical record review

    Time frame: Up to 21 days

  3. Duration of antibiotic use as measured by medical record review

    Duration will be measured in days

    Time frame: Up to 21 days

  4. Number of times participant represents with UTI symptoms as measured by medical record review

    Duration will be measured in days

    Time frame: Up to 30 days

  5. Number of additional diagnostic procedures related to initial presenting symptoms as measured by medical record review

    Time frame: Up to 21 days

  6. Number of hospitalizations related to UTI as measured by medical record review

    Time frame: Up to 21 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for May 2027, 19 months after the start.

Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's planned 19 months is below that.

Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → May 2027 and completion Sep 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 5, 2025
StartActual
Oct 22, 2025
Primary completionEst.
May 30, 2027was Sep 2026
CompletionEst.
May 30, 2027was Sep 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→May 30, 2027
Nov 5, 2026
Study completion
Sep 30, 2026→May 30, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Sep 30, 2026→May 30, 2027
    Study completion Sep 30, 2026→May 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06808451
Responsible party
David Sheyn (Director, Division of Urogynecology and Reconstructive Pelvic Surgery, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Feb 5, 2025
Start date
Oct 22, 2025
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Diana N Mitchell, MD, MBA, BSN
Contact
diana.mitchell@uhhospitals.org
216-844-1000
David Sheyn, MD
principal investigator · University Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion